Heart disease remains the leading cause of death in the United States, often striking without prior symptoms. Addressing this silent threat, Cleerly, a cardiovascular imaging startup, employs artificial intelligence (AI) to detect early-stage coronary artery disease (CAD) through detailed analysis of CT scans. This innovative approach parallels the preventive capabilities of mammograms and colonoscopies in cancer detection.
The Genesis of Cleerly
Founded in 2017 by Dr. James K. Min, a board-certified cardiologist and former Professor of Radiology and Medicine at Weill Cornell Medical College, Cleerly emerged from a clinical program initiated by Dr. Min in 2003 at NewYork-Presbyterian Hospital/Weill Cornell Medicine. With over 500 peer-reviewed publications, Dr. Min’s cardiovascular disease prevention and imaging expertise laid the groundwork for Cleerly’s mission to revolutionize heart disease diagnosis.
AI-Driven Diagnostic Innovation
Cleerly’s platform leverages AI to analyze coronary computed tomography angiography (CCTA) images comprehensively. This technology enables precise identification and quantification of atherosclerotic plaque, offering a non-invasive alternative to traditional diagnostic methods. By providing detailed insights into plaque characteristics and distribution, Cleerly’s AI facilitates early detection and personalized treatment strategies for CAD.
Addressing the Asymptomatic Challenge
A significant challenge in combating heart disease is that many individuals remain unaware of their condition until a heart attack occurs. Dr. Min emphasizes the importance of proactive screening, stating, “The majority of people who will die of heart disease and heart attacks will never have any symptoms. At some point, we need to start screening the world for heart disease.”
Strategic Partnerships and Expansion
In September 2024, Cleerly partnered with Viz.ai, integrating AI-driven diagnostics into the Viz.ai One platform. This collaboration aims to enhance care coordination for patients with heart disease, facilitating earlier detection and intervention.
Furthering its mission, Cleerly announced a partnership with Heartbeat Health in November 2022. This alliance combines Cleerly’s AI-enabled approach with Heartbeat Health’s nationwide network of virtual cardiologists to improve early detection and management of heart disease.
Financial Milestones and Recognition
Cleerly’s innovative approach has attracted significant investment. In December 2024, the company closed a Series C extension funding round, raising $106 million, led by Insight Partners and with participation from Battery Ventures and existing investors. This funding supports the expansion of Cleerly’s AI-driven platform and its integration into clinical practice.
The company’s contributions have also been recognized within the industry. Cleerly received the “Best Overall AI Solution” award in the sixth annual AI Breakthrough Awards program, underscoring its impact on transforming heart disease care through innovative AI-powered solutions.
The Future of Heart Disease Prevention
Cleerly’s AI-enabled CCTA analysis significantly advances non-invasive heart disease diagnostics. By providing detailed assessments of coronary health, Cleerly empowers physicians to implement preventive measures, potentially reducing the incidence of heart attacks. Dr. Min articulates that the goal is to “redefine cardiovascular care by leveraging AI technologies to help physicians better identify at-risk patients and provide the most effective preventive and precision heart care.”
As heart disease continues to pose a significant health challenge, Cleerly’s innovative use of AI in early detection and personalized care offers a promising path toward reducing mortality and improving patient outcomes.
